Literature DB >> 11262202

Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1.

C S Dezzutti1, P C Guenthner, J E Cummins, T Cabrera, J H Marshall, A Dillberger, R B Lal.   

Abstract

Primary prostate and cervical epithelial cells and epithelial cell lines were examined for human immunodeficiency virus type 1 (HIV-1) infection or transmission to peripheral blood mononuclear cells (PBMC). Neither cell-free nor cell-associated HIV-1 infected primary epithelial cells or cell lines. Pretreatment of HIV-1 to enhance CD4-independent entry did not augment infection. Cell surface expression was detected for galactosyl ceramide but not for CC-chemokine receptor 5, CXC-chemokine receptor 4, or CD4. The ability to transfer HIV-1 to resting or activated PBMC was tested by culturing with rinsed or trypsinized and replated HIV-1-exposed epithelial cells. Virus was not recovered from the rinsed or replated cocultures with resting PBMC; however, activated PBMC recovered HIV-1 from rinsed epithelial cells and rarely from replated epithelial cells. Although urogenital epithelial cells are not infected, these data suggest that they can transfer virus to activated immune cells and have implications for sexual transmission of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262202     DOI: 10.1086/319676

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

Review 1.  Interactions between HIV-1 and mucosal cells in the female reproductive tract.

Authors:  Ruizhong Shen; Holly E Richter; Phillip D Smith
Journal:  Am J Reprod Immunol       Date:  2014-04-01       Impact factor: 3.886

2.  Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Authors:  Nicholas J Mantis; Jana Palaia; Ann J Hessell; Simren Mehta; Zhiyi Zhu; Blaise Corthésy; Marian R Neutra; Dennis R Burton; Edward N Janoff
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 3.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

4.  HIV binding, penetration, and primary infection in human cervicovaginal tissue.

Authors:  Diane Maher; Xiaoyun Wu; Timothy Schacker; Julie Horbul; Peter Southern
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

Review 5.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

Review 6.  Innate and adaptive anti-HIV immune responses in the female reproductive tract.

Authors:  Marta Rodriguez-Garcia; Mickey V Patel; Charles R Wira
Journal:  J Reprod Immunol       Date:  2013-03       Impact factor: 4.054

Review 7.  HIV infection of the genital mucosa in women.

Authors:  Florian Hladik; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

8.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Rectal microbicide development.

Authors:  Ian McGowan; Charlene Dezzutti
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

10.  Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo.

Authors:  Anna Le Tortorec; Anne-Pascale Satie; Hélène Denis; Nathalie Rioux-Leclercq; Laurence Havard; Annick Ruffault; Bernard Jégou; Nathalie Dejucq-Rainsford
Journal:  Retrovirology       Date:  2008-12-31       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.